Investment Rating - The investment rating for the company is "Outperform Industry" with a target price of RMB 21.60, representing a potential upside of 29.8% from the current stock price of RMB 16.64 [3][7]. Core Insights - The company's 2023 performance was below expectations, with revenue of RMB 5.523 billion, a year-on-year growth of 1.4%, and a net profit attributable to the parent company of RMB 1.033 billion, growing by 12.2% [6][10]. - The CDMO (Contract Development and Manufacturing Organization) segment showed robust growth, achieving revenue of RMB 4.079 billion in 2023, a year-on-year increase of 19.4% [6]. - The specialty API (Active Pharmaceutical Ingredient) business faced challenges, with revenue declining by 22.9% to RMB 1.261 billion due to intensified competition and market adjustments [6][10]. - The company is expanding its peptide conjugate drug technology platform, with significant progress in peptide synthesis and delivery, and plans to increase project acceptance in the future [6]. Financial Performance - The company reported a decrease in revenue projections for 2024 by 27.6% to RMB 6.283 billion and introduced a new profit forecast for 2025 at RMB 14.04 billion [10]. - The adjusted net profit forecast for 2024 is RMB 1.183 billion, down by 17.9% from previous estimates [10]. - Key financial metrics include a projected P/E ratio of 12.7 for 2024 and 10.7 for 2025, with a P/B ratio of 1.6 for 2024 [7][10].
CDMO稳健增长,原料药板块承压